OneMedNet reports $18.76 million in year-to-date bookings, up sharply from 2025
OneMedNet said contracted demand now stands at nearly 14 times full-year 2025 bookings, with about half of 2026 contracts coming from new customers.
OneMedNet Corporation announced on November 9, 2026 that bookings reached approximately $18.76 million year-to-date as of November 6, 2026, of which $1.388 million has been converted to revenue through September 30, 2026.1
The announcement came alongside a growth recap the company called "OneMedNet by the Numbers," summarizing the company's commercial and operational trajectory, drawn from its November 6, 2026 financial outlook, prior public disclosures, and SEC filings.1
The release did not break out new bookings figures beyond the headline total, but it follows the company's November 6, 2026 disclosure in which it said it expects to report revenue of approximately $1 million for the quarter ended September 30, 2026, representing a 242% increase from the prior quarter ended June 30, 2026, and a 465% increase from the prior-year quarter ended September 30, 2025.2 That release also said the company forecasts revenue of approximately $12 million to $14 million for the fourth quarter of 2026, pending the anticipated acceptance of delivered data by customers.2
The November 6 filing noted that third quarter 2026 revenue results are preliminary and are subject to finalization and adjustment in connection with the preparation of the company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2026, which it expects to release by November 16, 2026.2
CEO Aaron Green said in the November 9 release, "Our strategy is working," adding that the company has focused on building relationships with industry leaders that already hold contracts across pharma and foundational AI, streamlining the contracting process and reducing time to booking, with a platform that allows it to deliver multi-modal data at the scale these customers require.1
OneMedNet described itself as operating a network spanning more than 2,300 sites and encompassing over 90 million patient journeys and 270 million studies, serving life sciences companies, medical device manufacturers, AI developers, and other innovators seeking high-quality, compliant healthcare data.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.